Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MURANASDAQ:NEUPNYSE:OSTXNASDAQ:PMVP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMURAMural Oncology$2.63-4.4%$2.20$0.95▼$4.74$45.42M3.911.31 million shs107,824 shsNEUPNeuphoria Therapeutics Inc. - Common Stock$6.74-0.6%$5.27$2.12▼$12.72$12.67M0.26354,096 shs175,372 shsOSTXOS Therapies$1.60-4.8%$1.63$1.12▼$7.00$44.96MN/A472,931 shs153,233 shsPMVPPMV Pharmaceuticals$0.90-0.7%$0.98$0.81▼$2.07$46.76M1.5232,538 shs452,558 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMURAMural Oncology-4.36%-11.74%+1.15%-30.61%-26.74%NEUPNeuphoria Therapeutics Inc. - Common Stock-0.59%+24.81%+33.73%+31.13%+673,999,900.00%OSTXOS Therapies-4.76%+0.63%0.00%-3.61%+159,999,900.00%PMVPPMV Pharmaceuticals-0.66%-3.31%-13.46%-37.06%-55.88%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMURAMural Oncology2.0155 of 5 stars3.32.00.00.01.31.71.3NEUPNeuphoria Therapeutics Inc. - Common Stock1.6933 of 5 stars3.50.00.00.02.80.00.6OSTXOS Therapies1.8972 of 5 stars3.70.00.00.01.21.70.6PMVPPMV Pharmaceuticals2.4992 of 5 stars3.52.00.00.03.51.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMURAMural Oncology 2.60Moderate Buy$13.00394.30% UpsideNEUPNeuphoria Therapeutics Inc. - Common Stock 3.00Buy$21.00211.57% UpsideOSTXOS Therapies 3.40Buy$18.001,025.00% UpsidePMVPPMV Pharmaceuticals 3.00Buy$5.50511.11% UpsideCurrent Analyst Ratings BreakdownLatest NEUP, MURA, OSTX, and PMVP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/22/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/7/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/2/2025OSTXOS TherapiesLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$19.003/31/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.003/26/2025MURAMural OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $6.003/25/2025MURAMural OncologyMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight3/25/2025MURAMural OncologyRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$18.003/25/2025MURAMural OncologyJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold3/20/2025PMVPPMV PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/12/2025MURAMural OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMURAMural OncologyN/AN/AN/AN/A$15.81 per shareN/ANEUPNeuphoria Therapeutics Inc. - Common Stock$15.66M0.81N/AN/A$7.82 per share0.86OSTXOS TherapiesN/AN/AN/AN/AN/AN/APMVPPMV PharmaceuticalsN/AN/AN/AN/A$4.41 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMURAMural Oncology-$207.45M-$7.67N/AN/AN/AN/A-70.10%-61.30%8/12/2025 (Estimated)NEUPNeuphoria Therapeutics Inc. - Common Stock-$15.49MN/A0.00N/AN/AN/AN/AN/AN/AOSTXOS Therapies-$7.79M-$0.86N/AN/AN/AN/AN/A-569.57%N/APMVPPMV Pharmaceuticals-$68.96M-$1.18N/AN/AN/AN/A-24.20%-21.67%8/14/2025 (Estimated)Latest NEUP, MURA, OSTX, and PMVP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q3 2025NEUPNeuphoria Therapeutics Inc. - Common Stock-$0.47$6.55+$7.02$6.55N/A$15.00 million5/14/2025Q1 2025MURAMural Oncology-$2.12-$1.93+$0.19-$1.93N/AN/A5/9/2025Q1 2025PMVPPMV Pharmaceuticals-$0.37-$0.34+$0.03-$0.34N/AN/A3/11/2025Q4MURAMural Oncology-$1.96-$2.01-$0.05-$2.01N/AN/A3/3/2025Q4 2024PMVPPMV Pharmaceuticals-$0.37-$0.45-$0.08-$0.45N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMURAMural OncologyN/AN/AN/AN/AN/ANEUPNeuphoria Therapeutics Inc. - Common StockN/AN/AN/AN/AN/AOSTXOS TherapiesN/AN/AN/AN/AN/APMVPPMV PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMURAMural OncologyN/A7.387.38NEUPNeuphoria Therapeutics Inc. - Common StockN/A2.063.30OSTXOS TherapiesN/A0.760.76PMVPPMV PharmaceuticalsN/A13.9813.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMURAMural Oncology80.21%NEUPNeuphoria Therapeutics Inc. - Common Stock15.90%OSTXOS TherapiesN/APMVPPMV Pharmaceuticals90.20%Insider OwnershipCompanyInsider OwnershipMURAMural Oncology0.06%NEUPNeuphoria Therapeutics Inc. - Common Stock0.69%OSTXOS Therapies13.80%PMVPPMV Pharmaceuticals7.57%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMURAMural Oncology11917.27 million17.01 millionOptionableNEUPNeuphoria Therapeutics Inc. - Common StockN/A1.88 million1.75 millionN/AOSTXOS TherapiesN/A28.10 millionN/AN/APMVPPMV Pharmaceuticals5051.95 million47.81 millionOptionableNEUP, MURA, OSTX, and PMVP HeadlinesRecent News About These CompaniesPMV Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences on Oncology Innovation and Healthcare AdvancesMay 23, 2025 | quiverquant.comPMV Pharmaceuticals to Participate at Upcoming Investor ConferencesMay 23, 2025 | globenewswire.comWe're Keeping An Eye On PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn RateMay 18, 2025 | finance.yahoo.comPMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate HighlightsMay 9, 2025 | finanznachrichten.dePMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate HighlightsMay 9, 2025 | finance.yahoo.comPMV Pharmaceuticals (PMVP) Projected to Post Quarterly Earnings on ThursdayMay 3, 2025 | marketbeat.comPMV Pharmaceuticals (NASDAQ:PMVP) Stock Price Down 3.7% - Should You Sell?April 28, 2025 | marketbeat.comWhy PMV Pharmaceuticals, Inc.’s (PMVP) Stock Is Up 7.83%April 21, 2025 | aaii.comHere's Why PMV Pharmaceuticals (PMVP) Looks Ripe for Bottom FishingMarch 5, 2025 | zacks.comPMV Pharmaceuticals reports FY24 EPS ($1.14), consensus ($1.02)March 3, 2025 | markets.businessinsider.comPMV Pharmaceuticals sees cash runway to end of 2026March 3, 2025 | markets.businessinsider.comPMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate HighlightsMarch 3, 2025 | globenewswire.comPMV Pharmaceuticals to Participate at Upcoming Investor ConferencesFebruary 11, 2025 | globenewswire.comPMV Pharmaceuticals stock hits 52-week low at $1.32January 21, 2025 | msn.comPMV Pharmaceuticals files $200M mixed securities shelfNovember 22, 2024 | markets.businessinsider.comPMV Pharmaceuticals upgraded to Outperform from Perform at OppenheimerNovember 9, 2024 | markets.businessinsider.comPMV Pharmaceuticals Reports Third Quarter 2024 Financial ResultsNovember 7, 2024 | markets.businessinsider.comOppenheimer Sticks to Its Hold Rating for PMV Pharmaceuticals (PMVP)October 25, 2024 | markets.businessinsider.comPMV Pharmaceuticals (PMVP) Gets a Buy from Craig-HallumOctober 25, 2024 | markets.businessinsider.comPMV Pharmaceuticals Provides a Progress Update on PYNNACLE Clinical TrialOctober 23, 2024 | finance.yahoo.comPMV provides update on Phase 2, Phase 1b portions of PYNNACLE trialOctober 23, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNEUP, MURA, OSTX, and PMVP Company DescriptionsMural Oncology NASDAQ:MURA$2.63 -0.12 (-4.36%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$2.64 +0.00 (+0.19%) As of 05/27/2025 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.Neuphoria Therapeutics Inc. - Common Stock NASDAQ:NEUP$6.74 -0.04 (-0.59%) As of 05/27/2025 04:00 PM EasternNeuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.OS Therapies NYSE:OSTX$1.60 -0.08 (-4.76%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$1.63 +0.03 (+1.94%) As of 05/27/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.PMV Pharmaceuticals NASDAQ:PMVP$0.90 -0.01 (-0.66%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$0.89 -0.01 (-0.78%) As of 05/27/2025 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Apple Sinks After New 25% Tariff Announcement—What's The Bottom? MarketBeat Week in Review – 05/19 - 05/23 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
